var data={"title":"Lixisenatide: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Lixisenatide: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/761551?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=lixisenatide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Lixisenatide: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48915856\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Adlyxin;</li>\n      <li>Adlyxin Starter Pack</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26595445\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidiabetic Agent, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48915871\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetes mellitus, type 2:</b> SubQ: Initial: 10 mcg once daily for 14 days; on day 15 increase to 20 mcg once daily. Maintenance dose: 20 mcg once daily.</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">\n      <i>Missed dose: </i>If dose is missed, administer within one hour of next meal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48915872\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48915873\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">eGFR &ge;30 to 89 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary; monitor closely for increased adverse GI effects (eg, diarrhea, nausea, vomiting) which may lead to dehydration and worsening of renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">eGFR 15 to 29 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (limited data); exposure is increased in these patients. Monitor closely for increased adverse GI effects (eg, diarrhea, nausea, vomiting) which may lead to dehydration and worsening of renal function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">eGFR &lt;15 mL/minute/1.73 m<sup>2</sup>: Use is not recommended (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48915874\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied); however, dosage adjustment not likely as hepatic impairment is not expected to affect lixisenatide pharmacokinetics.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49296567\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pen-injector Kit, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adlyxin Starter Pack: 10 mcg/0.2 mL &amp; 20 mcg/0.2 mL (3 mL) [contains metacresol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Pen-injector, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adlyxin: 20 mcg/0.2 mL (3 mL) [contains metacresol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49296566\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48915878\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Subcutaneous: Administer subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites for each dose; do not use the same site for each injection. Administer within one hour before the first meal of the day, preferably the same meal each day. Solution should appear clear and colorless; do not use if particulate matter or coloration is seen.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26595447\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Diabetes mellitus, type 2: </b>Treatment of type 2 diabetes mellitus (noninsulin dependent, NIDDM) to improve glycemic control in adult patients as an adjunct to diet and exercise</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46992935\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Gastrointestinal symptoms (40%; most were mild to moderate and within the first 3 weeks of starting treatment), nausea (25%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (70%: 2% had high antibody concentrations [&gt;100 nmol/L] and experienced an attenuated glycemic response)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (9%), dizziness (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (10%), diarrhea (8%), constipation (3%), dyspepsia (3%), abdominal distension (2%), upper abdominal pain (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (4%; including pain, pruritus, and erythema)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acute renal injury, hypersensitivity reaction, pancreatitis (acute, chronic, and edematous), renal insufficiency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26595451\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to lixisenatide or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48915860\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concerns related to adverse effects:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anti-lixisenatide antibodies: Use may be associated with the development of anti-lixisenatide antibodies. In clinical trials, high titers were observed in 2.4% of patients and were associated with an attenuated glycemic response. Allergic reactions and injection site reactions were more frequent in antibody positive patients; consider alternative antidiabetic therapy in patients not achieving targeted glycemic control or with worsening glycemic control and/or significant allergic or injection site reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported; discontinue use if hypersensitivity reactions occur and treat promptly as indicated. It is not known if patients with a history of hypersensitivity to other GLP-1 agonists are at increased risk for hypersensitivity reactions with lixisenatide; patients with prior serious reactions to similar agents should be monitored closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: Cases of acute pancreatitis (including hemorrhagic and necrotizing with some fatalities) have been reported; monitor for signs and symptoms of pancreatitis (eg, persistent severe abdominal pain which may radiate to the back, and which may or may not be accompanied by vomiting). If pancreatitis is suspected, discontinue use. Do not resume unless an alternative etiology of pancreatitis is confirmed. Consider alternative antidiabetic therapy in patients with a history of pancreatitis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Disease-related concerns:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastroparesis: Lixisenatide slows gastric emptying and is not recommended for use in patients with gastroparesis (has not been studied); do not initiate therapy in patients with severe gastroparesis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with mild renal impairment (eGFR &ge;60 to 89 mL/minute/1.73 m<sup>2</sup>) or moderate renal impairment (&ge;30 to &lt;60 mL/minute/1.73 m<sup>2</sup>); may be at increased risk of adverse effects (eg, diarrhea, nausea, vomiting) which may lead to dehydration, acute kidney injury and worsening of chronic renal failure. There is limited experience with severe impairment (eGFR 15 to &lt;30 mL/minute/1.73 m<sup>2</sup>); lixisenatide exposure may be increased in these patients. Monitor all patients with renal impairment closely for decreasing renal function. Use is not recommended in patients with end-stage renal disease (eGFR &lt;15 mL/minute/1.73 m<sup>2</sup>) (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Concurrent drug therapy issues: </b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Dosage form specific issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Multiple dose injection pens: According to the Centers for Disease Control and Prevention (CDC), pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of the risk of infection. The injection device should be clearly labeled with individual patient information to ensure that the correct pen is used (CDC 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Other warnings/precautions:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Not for use in patients with diabetic ketoacidosis (DKA) or patients with type 1 diabetes mellitus (insulin-dependent, IDDM).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46977088\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46977085\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=109304&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Androgens: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<b> Exceptions: </b>Danazol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): Lixisenatide may decrease the serum concentration of Estrogen Derivatives (Contraceptive).  Management: Administer oral contraceptives 1 hour before or at least 11 hours after administration of lixisenatide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Insulins: Glucagon-Like Peptide-1 Agonists may enhance the hypoglycemic effect of Insulins.  Management: Consider insulin dose reductions when used in combination with glucagon-like peptide-1 agonists. Avoid the use of lixisenatide in patients receiving  both basal insulin and a sulfonylurea.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegvisomant: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): Lixisenatide may decrease the serum concentration of Progestins (Contraceptive).  Management: Administer oral contraceptives 1 hour before or at least 11 hours after administration of lixisenatide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prothionamide: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Quinolones may diminish the therapeutic effect of Blood Glucose Lowering Agents. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Blood Glucose Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: Glucagon-Like Peptide-1 Agonists may enhance the hypoglycemic effect of Sulfonylureas.  Management: Consider sulfonylurea dose reductions when used in combination with glucagon-like peptide-1 agonists. Avoid the use of lixisenatide in patients receiving both basal insulin and a sulfonylurea.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48915858\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events were observed in some animal reproduction studies.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In women with diabetes, maternal hyperglycemia can be associated with congenital malformations as well as adverse effects in the fetus, neonate, and the mother (ACOG 60 2005; ADA 2018c; Kitzmiller 2008; Metzger 2007). To prevent adverse outcomes, prior to conception and throughout pregnancy maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ACOG 137 2013; ADA 2018c; Blumer 2013; Kitzmiller 2008). Prior to pregnancy, effective contraception should be used until glycemic control is achieved (ADA 2017c; Kitzmiller 2008). Other agents are currently recommended to treat diabetes in pregnant women (ACOG 137 2013; ADA 2018c; Blumer 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48915859\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if lixisenatide is excreted in breast milk. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of infant exposure, the benefits of breast-feeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48915876\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy (ADA 2016b).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48915881\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum glucose, hemoglobin A<sub>1c</sub> (at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; quarterly in patients not meeting treatment goals or with therapy change [ADA 2018a]), renal function, signs/symptoms of pancreatitis; signs/symptoms of adverse GI effects (diarrhea, nausea, vomiting); signs/symptoms of hypersensitivity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48915880\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Recommendations for glycemic control in nonpregnant adults with diabetes (ADA 2018a):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] HbA<sub>1c</sub> goal may be targeted based on patient-specific characteristics)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial capillary blood glucose: 80 to 130 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak postprandial capillary blood glucose: &lt;180 mg/dL</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Recommendations for glycemic control in older adults (&ge;65 years) with diabetes (ADA 2018b):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HbA<sub>1c</sub>: &lt;7.5% (healthy); &lt;8% (complex/intermediate health); &lt;8.5% (very complex/poor health) (individualization may be appropriate based on patient and caregiver preferences)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preprandial capillary blood glucose: 90 to 130 mg/dL (healthy); 90 to 150 mg/dL (complex/intermediate health); 100 to 180 mg/dL (very complex/poor health)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bedtime capillary blood glucose: 90 to 150 mg/dL (healthy); 100 to 180 mg/dL (complex/intermediate health); 110 to 200 mg/dL (very complex/poor health)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48915863\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Lixisenatide is a selective glucagon-like peptide-1 (GLP-1) receptor agonist. Acting on the same receptor as the endogenous hormone incretin, lixisenatide increases glucose-dependent insulin secretion, decreases inappropriate glucagon secretion, and slows gastric emptying.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48915864\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Vz/F: ~100 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Presumed to undergo proteolytic degradation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: 1 to 3.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49483331\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pen-injector Kit</b> (Adlyxin Starter Pack Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 &amp; 20MCG/0.2ML (3 mL): $353.71</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Pen-injector</b> (Adlyxin Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20MCG/0.2ML (3 mL): $353.71</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46972049\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Liksumiya (UA);</li>\n      <li>Lyxumia (AE, AR, AT, AU, BE, BR, CR, CY, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, IE, IL, IS, JP, KR, LB, LT, LU, LV, MT, MX, NI, NL, NO, NZ, PA, PH, PL, PT, QA, RO, SE, SI, SK, SV, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Adlyxin (lixisenatide) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 60, March2005. Pregestational diabetes mellitus. <i>Obstet Gynecol.</i> 2005;105(3):675-685.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lixisenatide-drug-information/abstract-text/15738045/pubmed\" target=\"_blank\" id=\"15738045\">15738045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins--Obstetrics. Practice Bulletin No. 137: Gestational diabetes mellitus. <i>Obstet Gynecol</i>. 2013;122(2 Pt 1):406-416. doi: 10.1097/01.AOG.0000433006.09219.f1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lixisenatide-drug-information/abstract-text/23969827/pubmed\" target=\"_blank\" id=\"23969827\">23969827</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29222377\"></a>American Diabetes Association (ADA). 6. Glycemic targets: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018a;41(suppl 1):S55-S64. doi: 10.2337/dc18-S006.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lixisenatide-drug-information/abstract-text/29222377/pubmed\" target=\"_blank\" id=\"29222377\">29222377</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"29222382\"></a>American Diabetes Association (ADA). 11. Older adults: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018b;41(suppl 1):S119-S125. doi: 10.2337/dc18-S011.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lixisenatide-drug-information/abstract-text/29222382/pubmed\" target=\"_blank\" id=\"29222382\">29222382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association (ADA). 13. Management of diabetes in pregnancy: standards of medical care in diabetes-2018. <i>Diabetes Care</i>. 2018c;41(suppl 1):S137-S143. doi: 10.2337/dc18-S013.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lixisenatide-drug-information/abstract-text/29222384/pubmed\" target=\"_blank\" id=\"29222384\">29222384</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(11):4227-4249. doi: 10.1210/jc.2013-2465.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lixisenatide-drug-information/abstract-text/24194617/pubmed\" target=\"_blank\" id=\"24194617\">24194617</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). CDC clinical reminder: insulin pens must never be used for more than one person. Centers for Disease Control and Prevention Web site. <a href=\"http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html\" target=\"_blank\">http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html</a>. Updated January 5, 2012. Accessed September 20, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kitzmiller JL, Block JM, Brown FM, et al. Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care. <i>Diabetes Care.</i> 2008;31(5):1060-1079. doi: 10.2337/dc08-9020.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lixisenatide-drug-information/abstract-text/18445730/pubmed\" target=\"_blank\" id=\"18445730\">18445730</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metzger BE, Buchanan TA, Coustan DR, et al. Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. <i>Diabetes Care</i>, 2007;30(Suppl 2):S251-S260. doi: 10.2337/dc07-s225.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/lixisenatide-drug-information/abstract-text/17596481/pubmed\" target=\"_blank\" id=\"17596481\">17596481</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 109304 Version 26.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F48915856\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F26595445\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F48915871\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F48915872\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F48915873\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F48915874\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F49296567\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F49296566\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F48915878\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F26595447\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F46992935\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F26595451\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F48915860\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F46977088\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F46977085\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F48915858\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F48915859\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F48915876\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F48915881\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F48915880\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F48915863\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F48915864\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F49483331\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F46972049\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/109304|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=lixisenatide-patient-drug-information\" class=\"drug drug_patient\">Lixisenatide: Patient drug information</a></li></ul></div></div>","javascript":null}